ORIGINAL RESEARCH article
Front. Med.
Sec. Pulmonary Medicine
Development of serum glycosylated exosomal microRNAs as biomarkers for early diagnosis of lung adenocarcinoma
Provisionally accepted- 1Fujian Children's Hospital, Fuzhou, China
- 2Fuzhou First General Hospital Affiliated with Fujian Medical University, Fuzhou, China
- 3Beijing Youngen Technology Co. Ltd., Beijing, China
- 4Beijing Hotgen Biotech Co Ltd, Beijing, China
- 5Xiamen University, Xiamen, China
- 6Fuzhou University Affiliated Provincial Hospital, Fuzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Early diagnosis is a major challenge in lung adenocarcinoma (LUAD). Tumor-derived exosomal microRNAs (miRNAs) are promising diagnostic biomarkers, and given the aberrant overexpression of tumor-associated glycans on exosomes, we employed a GlyExo-Capture approach using wheat germ agglutinin (WGA)- and lentil lectin (LCA)-coated magnetic beads to enrich glycosylated exosomes (WGA-and LCA-exosomes) from serum, and then detected exosomal miRNAs in 413 serum samples. Initially, small RNA sequencing was performed on a screening set (n=30) to obtain candidate WGA-exosomal miRNAs. Moreover, candidate WGA-exosomal miRNAs were identified through RT-qPCR to develop a predictive panel of candidate WGA-exosomal miRNAs combined with candidate LCA-exosomal miRNAs identified in our pilot study via an independent training set (n=254). Finally, the diagnostic value of the predictive panel for early LUAD was determined through a validation set (n=129). Results showed that WGA-and LCA-coated magnetic beads effectively enriched glycosylated exosomes from both the conditioned media of LUAD cells and the sera of LUAD patients. Furthermore, 4-miRNA panel of serum WGA-exosomal miR-199a-3p, miR-222-3p combined with serum LCA-exosomal miR-486-5p, miR-139-3p, was developed for early diagnosis of LUAD. In the training and validation sets, the area under the curve of the 4-miRNA panel was 0.909 and 0.942, respectively. These findings suggest that the serum glycosylated exosomal 4-miRNA panel developed using the GlyExo-Capture approach may serve as a promising strategy for liquid biopsy-based early detection of LUAD.
Keywords: Lung Adenocarcinoma, GlyExo-Capture approach, serum exosomal miRNA, early diagnosis, biomarkers
Received: 30 Aug 2025; Accepted: 21 Nov 2025.
Copyright: © 2025 Huang, Chen, Gao, Hao, Yu and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Chundong Yu, cdyu@xmu.edu.cn
Yi Huang, hyi8070@126.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
